189 related articles for article (PubMed ID: 26831408)
1. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Liu L; Zhao Y; Jia J; Chen H; Bai W; Yang M; Yin Z; He C; Zhang L; Guo W; Niu J; Yuan J; Cai H; Xia J; Fan D; Han G
Sci Rep; 2016 Feb; 6():19851. PubMed ID: 26831408
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
4. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatocellular carcinoma -- experience of a single center.
Iliescu L; Mindrut E; Grasu M; Orban C; Tanase A; Toma L
Chirurgia (Bucur); 2014; 109(2):204-7. PubMed ID: 24742411
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
7. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
9. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
10. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
Liu G; Ouyang Q; Xia F; Fan G; Yu J; Zhang C; Wang D
HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
[TBL] [Abstract][Full Text] [Related]
11. Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Ha Y; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Kang YK; Kim KM
Oncotarget; 2016 Nov; 7(45):74303-74313. PubMed ID: 27494871
[TBL] [Abstract][Full Text] [Related]
12. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
13. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Zhao Y; Li H; Bai W; Liu J; Lv W; Sahu S; Guan S; Qin X; Wang W; Ren W; Mu W; Guo W; Gu S; Ma Y; Yin Z; Guo W; Wang W; Wang Y; Duran R; Fan D; Zhang Z; Han G
Int J Cancer; 2016 Aug; 139(4):928-37. PubMed ID: 27038145
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
15. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
16. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Tian M; Zhang X; Huang G; Fan W; Li J; Zhang Y
Abdom Radiol (NY); 2019 Oct; 44(10):3304-3311. PubMed ID: 31250181
[TBL] [Abstract][Full Text] [Related]
18. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
20. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Katano Y; Hirooka Y; Ishikawa T; Nakano I; Goto H
PLoS One; 2015; 10(9):e0138776. PubMed ID: 26421430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
